Marta Gil-Martín
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers 28
- Cancer Treatment and Pharmacology 20
- HER2/EGFR in Cancer Research 17
- CAR-T cell therapy research 15
- Obstetrics and Gynecology top 5%
- Endometrial and Cervical Cancer Treatments 14
- Reproductive Medicine top 5%
- Ovarian cancer diagnosis and treatment 18
- Cancer Research top 5%
- Genetics top 5%
-
- Advanced Breast Cancer Therapies 22
- Lung Cancer Treatments and Mutations 12
Marta Gil-Martín
102 papers receiving 2.0k citations
Hit Papers
Peers
Comparison fields: 5 of 88
- Oncology 1.2k
- Obstetrics and Gynecology 216
- Reproductive Medicine 232
- Cancer Research 322
- Genetics 216
Countries citing papers authored by Marta Gil-Martín
This map shows the geographic impact of Marta Gil-Martín's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marta Gil-Martín with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marta Gil-Martín more than expected).
Fields of papers citing papers by Marta Gil-Martín
This network shows the impact of papers produced by Marta Gil-Martín. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marta Gil-Martín. The network helps show where Marta Gil-Martín may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Marta Gil-Martín, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 7 | |
| 6 | 2024 | 3 | |
| 7 | 2023 | 1 | |
| 8 | 2023 | 6 | |
| 9 | 2023 | 3 | |
| 10 | 2022 | 0 | |
| 11 | 2021 | 11 | |
| 12 | 2021 | 15 | |
| 13 | 2020 | 3 | |
| 14 | 2019 | 36 | |
| 15 | Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Studybreakdown → | 2018 | 302 |
| 16 | 2018 | 80 | |
| 17 | 2017 | 1 | |
| 18 | 2017 | 45 | |
| 19 | Phase III study of Ribociclib (LEE011) in combination with Fulvestrant for the treatment of postmenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who have received no or only one line of prior endocrine treatment : MONALEESA-3 | 2016 | 3 |
| 20 | 2012 | 5 |
About Marta Gil-Martín
Marta Gil-Martín is a scholar working on Oncology, Reproductive Medicine and Obstetrics and Gynecology, having authored 108 papers that have together received 2.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (28 papers), Advanced Breast Cancer Therapies (22 papers), Cancer Treatment and Pharmacology (20 papers), Ovarian cancer diagnosis and treatment (18 papers), HER2/EGFR in Cancer Research (17 papers), CAR-T cell therapy research (15 papers), Endometrial and Cervical Cancer Treatments (14 papers) and Lung Cancer Treatments and Mutations (12 papers). The work is most often cited by research in Oncology (1.2k citations), Obstetrics and Gynecology (216 citations) and Reproductive Medicine (232 citations). Marta Gil-Martín has collaborated with scholars based in Spain, United States and Germany. Frequent co-authors include Víctor Moreno, Cornelia Quadt, Valentina Boni, Douglas Bootle, David Demanse, Martin Schüler, Dejan Juric, José Baselga, Howard A. Burris and Ruth Seggewiss‐Bernhardt. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.